🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. Estradiol

    Teva Pharma GmbH

    Dyspareunia

    phase 3 small molecule completed

    1 trial

  2. Estradiol Vaginal Tablets 10 mcg

    Amneal Pharma Europe Ltd

    Atrophic Vaginitis Due to Menopause

    phase 3 small molecule completed

    1 trial

  3. Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)

    Bayer HealthCare AG

    Primary Dysmenorrhea

    phase 3 small molecule completed

    1 trial

  4. EstroTep 500 MBq/mL, solution injectable

    The George Institute

    Women with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitor

    phase 3 small molecule active

    1 trial

  5. Etavopivat A 100 mg, Etavopivat placebo., Etavopivat A 200 mg

    NovoThirteen

    sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  6. Etrasimod Arginine Blue

    Lacuna Pharma Pty Ltd

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  7. Etrasimod Arginine Blue Placebo, Etrasimod Arginine Blue, Etrasimod Arginine Blue

    Lacuna Pharma Pty Ltd

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  8. Everolimus-ratiopharm® 2,5 mg Tabletten, GOSERELIN , ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets, LEUPRORELIN , DEXAMETHASONE , The investigational product is as follows: white tablets, elongated, flat, rounded edges, about 10 mm long and 4 mm wide, with the embossing "EV" on one side and "2.5" on the other side. The list of excipients of Placebo tablet is as follows: Lactose monohydrate, Polyplasdone, Cellulose microcrystalline, Magnesium stearate, Hypromellose., TRIPTORELIN

    Stemline Therapeutics B.V.

    patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.

    phase 3 small molecule active

    1 trial

  9. Evinacumab

    Ultragenyx UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  10. Evolocumab

    COLLEGIUM PHARMACEUTICAL, INC

    Sars-CoV-2 Infection

    phase 3 small molecule completed

    1 trial

  11. Evolocumab

    Amgen

    Dyslipidemia

    phase 3 mab completed

    1 trial

  12. Evolocumab

    Amgen

    Hyperlipidemia

    phase 3 mab completed

    2 trials

  13. Evolocumab

    Amgen

    Coronary Heart Disease (CHD)

    phase 3 small molecule completed

    1 trial

  14. Evolocumab

    Amgen

    Severe Familial Hypercholesterolemia

    phase 3 mab completed

    1 trial

  15. Excipients without active substance - Lyophilised powder for solution for injection - Intramuscolar Use

    Ipsen

    Treatment of moderate to severe glabellar lines

    phase 3 small molecule active

    1 trial

  16. Expanded access program for mepolizumab in subjects with hypereosinophilic syndrome.

    GlaxoSmithKline

    Hypereosinophilic Syndrome

    phase 3 other active

    1 trial

  17. Exparel

    Pacira Ireland Limited

    Back Pain

    phase 3 small molecule active

    1 trial

  18. Exparel Injectable Product

    Pacira Ireland Limited

    Coronary Artery Disease

    phase 3 small molecule completed

    1 trial

  19. Experimental: Tezepelumab

    AstraZeneca

    Asthma

    phase 3 mab completed

    1 trial

  20. Experimental: Venetoclax in combination with Decitabine (+-sorafenib)

    Kunming Hope of Health Hospital

    Elderly AML Patients

    phase 3 other active

    1 trial

  21. Extended Release Buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorder

    phase 3 small molecule completed

    1 trial

  22. Extended Release Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 3 small molecule completed

    1 trial

  23. Extended treatment

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 3 small molecule completed

    1 trial

  24. Eylea (Aflibercept, BAY86-5321)

    Regeneron UK Limited

    Retinopathy of Prematurity (ROP)

    phase 3 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources